Wednesday, June 10

Browsing: Gedatolisib

Treatments

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

By NewsCancerMay 28, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

Support

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

By NewsCancerMay 27, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

Diagnosis

Gedatolisib Combinations Improve PFS in Advanced Breast Cancer

By NewsCancerMarch 10, 20260

The phase 3 VIKTORIA-1 trial (NCT05501886) demonstrated that adding the multitarget inhibitor gedatolisib to fulvestrant (Faslodex), both with and without…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC

Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection

Rethinking Academic Support: Sustainability For Clinical Cancer Research

Browsing: Gedatolisib

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

Gedatolisib Combinations Improve PFS in Advanced Breast Cancer

Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC

Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection

Rethinking Academic Support: Sustainability For Clinical Cancer Research

UK’s stem cell transplant system may be putting lives at risk, report by MPs finds | Stem cells

Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC

Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection

Rethinking Academic Support: Sustainability For Clinical Cancer Research

UK’s stem cell transplant system may be putting lives at risk, report by MPs finds | Stem cells

Latest Post

Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC

Differentiating malignancy from liver parenchyma in Ex-Vivo OCT images using anomaly detection

Rethinking Academic Support: Sustainability For Clinical Cancer Research

Subscribe to Updates

What's Hot

Browsing: Gedatolisib